HEALTHCARE & PHARMACEUTICALS MARKET RESEARCH
Category: Research
-
WHY IS OUR IMMUNE SYSTEM ATTACKING US?
When a foreign substance enters our body, it identifies the danger and our immune system then produces antibodies in response to the antigen that may be present on the surface of that substance. This is our body’s way of fighting against the infection and it is what we call an immune response. The antigen induces…
-
ZOLGENSMA: THE WORLD’S MOST EXPENSIVE DRUG @ £1.79 Million (Rs 18 Cr)
What is Zolgensma? It is an FDA-approved drug which is basically a type of gene replacement therapy used to treat spinal muscular atrophy(SMA) in paediatric patients. A single dose of this drug can provide a lifetime of benefit and save lives. The drug’s original developer is Avexis which has been acquired by Novartis in May…
-
NIPAH VIRUS : ALL THE INFORMATION YOU NEED
History of the Nipah virus in India In 2001, the first outbreak of Nipah virus was occurred in West Bengal that caused as many as 45 deaths. Again, it happened there in 2007 and 5 people lost their lives. In Kozhikode, it all started in May, 2018 when the first Nipah virus disease outbreak was…
-
NEEDLE FREE BLOOD SUGAR TEST
Scientists at University of Newcastle in Australia have successfully developed a non-invasive, printable saliva test strip for diabetics to check glucose levels. In contrary to the current needle-based test, this discovery brings a pain free method for blood sugar testing of diabetes patients. Several patients do not tend to test as often as they ideally…
-
HOW LIKELY IS THE THIRD WAVE IN INDIA?
Several speculations are doing the rounds regarding the possibility of a third wave and if children are at a risk of getting infected in the subsequent wave. There is a lot of misinformation involved; however certain things need to be understood and implemented accurately so that we can look towards a foreseeable post pandemic future…
-
NEW COVID TREATMENT IN INDIA: ANTIBODY COCKTAIL BY ROCHE AND CIPLA
The monoclonal antibody cocktail, effective against the B.1.617 variant (found in India) is being imported by Roche, a Switzerland-based leading healthcare company and marketed in India through Cipla Ltd has recently received Emergency Use Authorization (EUA) from Central Drug Standard Control Organization (CDSCO) for the treatment of mild to moderate Covid-19 in adults and pediatric…
-
Everything you should know about 2-DG : DRDO’S exciting new anti-COVID drug
Everything you need to know about 2-DG : DRDO’S new anti-COVID drug
-
NEW AUSTRALIAN COVID VACCINE TO COMPLETELY PREVENT COVID-19 TRANSMISSION
An Adelaide based company, Vaxine Pty Ltd has successfully developed a COVID vaccine, COVAX-19 that holds the ability to completely prevent the covid-19 virus transmission in non-immune individuals. No other vaccine in the world has been yet found to show such promising results. COVAX-19 vaccine is a subunit vaccine based on synthetic protein produced using…
Follow Us
Recent Posts
-
Bedaquiline Role in Treating Tuberculosis having a hefty $1.38 billion dollar market
-
Adalimumab’s competition and immense market Growth Potential of 5.1%
-
Semaglutide’s massive influence on the Diabetes Pharmaceutical Market and 6 competitors
-
FDA approved Leqembi to have $12.9 billion sales
-
Assistive Technology Market; a $82B Growth Story
Tags
Autoimmunity cancer cancer research cancer therapy CDSCO covid-19 covid in children Diabetes drug Elderly Health FDA healthcare immune response Kerala mutations Nipah virus pandemic PCOS pharma Pharmaceutical market pharma sector protein-based vaccines sars-cov-2 therapy third wave Treatment vaccine variants WHO zydus cadila